ReviewCureus2020
Multiple Sclerosis and Serotonin: Potential Therapeutic Applications.
Review in Cureus, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 31 citations in OpenAlex.
- Flunarizine prevents demyelination and neurological deficits in a cuprizone-induced mouse model of multiple sclerosis.Indian journal of pharmacology · 2026Article
- Review
- 1,3,4 oxadiazole derivative attenuates neurotransmitter-mediated inflammatory response in EAE model of multiple sclerosis.Scientific reports · 2026Article
- Reduced peripheral serotonin levels in women with multiple sclerosis: associations with underweight status, treatment duration, and use of interferon beta 1a.Frontiers in cellular neuroscience · 2026Article
- Decoding GPCR signaling in living cells to advance early therapeutic discovery for neurological disorders.Frontiers in molecular neuroscience · 2026Review
- Linking Nutrients to Multiple Sclerosis Pathogenesis: Biological Evidence and Clinical Implications.Nutrients · 2025Review
- From Multiple Sclerosis to Organ-Specific Autoimmune Disorders: Insights into the Molecular and Clinical Implications of Comorbidity.Molecular neurobiology · 2025Review
- Plasma and Visceral Organ Kynurenine Metabolites Correlate in the Multiple Sclerosis Cuprizone Animal Model.International journal of molecular sciences · 2025Article
- Behavioral disorders in multiple sclerosis: a comprehensive review.Journal of neural transmission (Vienna, Austria : 1996) · 2025Review
- Oculomics analysis in multiple sclerosis: Current ophthalmic clinical and imaging biomarkers.Eye (London, England) · 2024Review
- Gut Bacteria Provide Genetic and Molecular Reporter Systems to Identify Specific Diseases.International journal of molecular sciences · 2024Review
- Obsessive-compulsive symptoms and brain lesions compatible with multiple sclerosis.Journal of neural transmission (Vienna, Austria : 1996) · 2024Article
- From intestinal metabolites to the brain: Investigating the mysteries of Long COVID.Clinical and translational medicine · 2024Article
- Review
- Article
- Review
- Tryptophan Metabolism in Central Nervous System Diseases: Pathophysiology and Potential Therapeutic Strategies.Aging and disease · 2023Review
- T Lymphocyte Serotonin 5-HTBiomedicines · 2022Article
- A gut-centric view of aging: Do intestinal epithelial cells contribute to age-associated microbiota changes, inflammaging, and immunosenescence?Aging cell · 2022Review
- Bacterial neurotoxic metabolites in multiple sclerosis cerebrospinal fluid and plasma.Brain : a journal of neurology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis (MS) is a neurodegenerative disease with a complex autoimmune component, and it has a high prevalence among middle-aged females. The manifestations of the disease range from episodic somatosensory dysfunction to progressive and permanent central nervous system (CNS) damage. Due to a high prevalence of psychiatric comorbidities and proven abnormalities in serotonin (5-HT) levels among MS patients, they are usually on drugs that modify the serotonergic system. Through a comprehensive literature review of studies published in the last 10 years related to 5-HT in MS and its therapeutic applications, we aimed to elucidate the mechanism behind the neurotransmitter (NT) levels' abnormalities. Most importantly, we endeavored to gather the most up-to-date information about the full therapeutic potential of agents acting on this system. We discovered that multiple processes cause low levels of 5-HT in MS patients. The varying levels of the availability of the 5-HT transporter (SERT) in the CNS decreasing overall tryptophan (TRP) levels, and diversion of the amino acid away from its synthetic pathway constitute some of those. Studies in animals have shown that 5-HT levels' elevations could cause immune-modulating effects and could probably slow down the disease progression rate. Human studies have shown a more diverse and complex response. Promising results have been obtained in the last 10 years regarding 5-HT's immune-modulatory role in MS patients and its therapeutic applications. Human studies with a larger population and feasible designs are still needed to fully ascertain the effects of serotonin on the immune system and disease progression in patients with MS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.